Sun Pharma to Revitalize Portfolio, Expand Licensing Opportunities Following Organon Acquisition

Sun Pharmaceutical Industries Acquires Organon as Platform for Global Growth

Sun Pharmaceutical Industries is positioning its $11.75-billion acquisition of Organon as a long-term platform to license late-stage assets in women's health, biosimilars, and other innovative therapies, as it looks to fuel the company's next phase of global growth.

The acquisition gives Sun Pharma a ready-made engine to in-license near-approval products and scale them quickly across markets where Sun Pharma either has no presence or relies on distributors. Organon's commercial footprint across more than 140 countries provides a significant advantage in licensing and launching products in various markets. In women's health alone, there are more than 100 assets under development globally, and having a global commercial platform materially improves Sun Pharma's ability to license such products and launch them meaningfully.

The investor presentation highlights women's health as a $35-billion-plus market growing at 6-10 percent annually, and biosimilars as a segment with over $70 billion in potential opportunity from upcoming loss-of-exclusivity events. Innovative medicines, including women's health, contributed about one-third of Organon's $6.2 billion revenue in 2025, while biosimilars accounted for about 11%. Both segments posted modest growth.

Read also: Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4

Equally critical to the investment case is Sun's plan to reinvigorate Organon's large but stagnant portfolio of established brands, which accounts for 51 percent of Organon's revenues but has delivered flat to negative growth in recent years. Sun Pharma believes its branded-generics playbook—line extensions, reformulations, and new combinations—can revive Organon's established brands, particularly in emerging markets where brand equity remains crucial.

The company has guided to potential cost synergies of more than $350 million over two to four years, largely from procurement efficiencies and operational scale. Sun Pharma plans to fund the $3.9-billion equity portion largely through internal cash accruals, while $9.25-$9.75 billion will be financed through committed bank borrowings. The company estimates the merged business will generate about $2.5 billion in annual cash flows, which it plans to deploy first toward debt reduction, while continuing to invest in R&D and licensing.

Sun has already set up an Integration Management Office to plan post-close execution, drawing talent from both companies while observing regulatory firewalls. Management said execution will begin on "Day 1" of closing, with the deal expected to close in six to nine months, subject to shareholder and regulatory approvals.

Read also: MarketSmith India's 4 June Stock Recommendations

HDFC Securities, in its latest report on the deal, said the acquisition "provides scale" and access to new growth platforms, but flagged that reviving growth in established brands and integrating two large global organisations will be the key near-term challenges. The brokerage expects the deal to be earnings-accretive from year one, but warned that combined revenue growth could temporarily slow to mid-single digits as Sun Pharma digests the acquisition.